BiotechTube

Ruxolitinib Cream + Vehicle Cream

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Jun 12, 2025 → Jul 11, 2027

NCT ID
NCT06958211

About Ruxolitinib Cream + Vehicle Cream

Ruxolitinib Cream + Vehicle Cream is a phase 3 stage product being developed by Incyte for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06958211. Target conditions include Hidradenitis Suppurativa.

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa were approved

Approved (1) Terminated (0) Active (19)
✅Placebo + AdalimumabAbbVieApproved
🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3
🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3
🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
🔄Lutikizumab + PlaceboAbbViePhase 3
🔄Upadacitinib + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT06804811Phase 3Recruiting
NCT06959225Phase 3Recruiting
NCT06958211Phase 3Recruiting
NCT06548360Phase 3Recruiting
NCT06238817Phase 3Completed
NCT05764161Phase 3Completed
NCT05755438Phase 3Completed
NCT05635838Phase 2Completed
NCT05593432Phase 2Completed
NCT05593445Phase 2Completed
NCT04896385Phase 2Completed
NCT03745638Phase 3Completed
NCT03745651Phase 3Completed
NCT03099304Phase 2Completed

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Eltrekibart + PlaceboEli LillyPhase 2
39
Placebo + LY3041658Eli LillyPhase 2
35
Placebo + AdalimumabAbbVieApproved
43
Lutikizumab + PlaceboAbbViePhase 3
47
AdalimumabAbbViePre-clinical
26
Upadacitinib + PlaceboAbbViePhase 3
47
adalimumab + placeboAbbViePhase 3
40
LutikizumabAbbViePhase 2
42
adalimumabAbbViePhase 3
40
Lutikizumab + PlaceboAbbViePhase 2
39
Risankizumab + Placebo for risankizumabAbbViePhase 2
35
adalimumabAbbViePhase 3
40
adalimumab + placeboAbbViePhase 3
40
Upadacitinib + PlaceboAbbViePhase 2
35
MEDI8968 + SalineAstraZenecaPhase 2
27